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Pharmaceutical Industry in Uganda:
A Review of the Common GMP Non-conformances during 
Regulatory Inspections
N. Lubowa1, Z. Ekeocha2, S. Byrn3, K. Clase4 
ABSTRACT
The prevalence of substandard medicines in Africa is high but not well documented. Low and Middle-Income Countries
(LMICs) are likely to face considerable challenges with substandard medications. Africa faces inadequate drug
regulatory practices, and in general, compliance with Good Manufacturing Practices (GMP) in most of the 
pharmaceutical industries is lacking. The majority of pharmaceutical manufacturers in developing countries are often 
overwhelmed by the GMP requirements and therefore are unable to operate in line with internationally acceptable
standards. Non-conformances observed during regulatory inspections provide the status of the compliance to GMP
requirements.
The study aimed to identify the GMP non-conformances during regulatory inspections and gaps in the production of
pharmaceuticals locally manufactured in Uganda by review of the available 50 GMP reports of 21 local
pharmaceutical companies in Uganda from 2016. The binary logistic generalized estimating equations (GEE) model
was applied to estimate the association between odds of a company failing to comply with the GMP requirements
and non-conformances under each GMP inspection parameter. Analysis using dummy estimation to linear regression
included determination of the relationship that existed between the selected variables (GMP inspection parameters)
and the production capacity of the local pharmaceutical industry.
Oral liquids, external liquid preparations, powders, creams, and ointments were the main categories of products
manufactured locally. The results indicated that 86% of the non-conformances were major, 11% were minor, and 3%
critical. The majority of the non-conformances were related to production (30.1%), documentation (24.5%), and
quality control (17.6%). Regression results indicated that for every non-conformance under premises, equipment,
and utilities, there was a 7-fold likelihood of the manufacturer failing to comply with the GMP standards (aOR=6.81,
P=0.001). The results showed that major non-conformances were significantly higher in industries of small scale
(B=6.77, P=0.02) and medium scale (B=8.40, P=0.04), as compared to those of large scale.
This study highlights the failures in quality assurance systems and stagnated GMP improvements in these industries
that need to be addressed by the manufacturers with support from the regulator. The addition of risk assessment to
critical production and quality control operations and establishment of appropriate corrective and preventive actions
as part of quality management systems are required to ensure that quality pharmaceuticals are manufactured locally.
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1. INTRODUCTION
Pharmaceutical manufacturing is a capital-intensive
venture that requires a lot of financial investment to 
establish a facility that meets internationally acceptable 
Good Manufacturing Practice (GMP) standards (UNIDO, 
2013). There were 21 registered pharmaceutical
industries in Uganda in 2019, of which the majority are 
small scale industries. Uganda pharmaceutical market
imports 90 percent of the medicines from mainly India 
and China, implying that 10 percent of the drugs are by 
local manufacturers (Gilbert O. et al., 2015). Therefore,
the industries in Uganda cannot meet the required 
pharmaceutical market demands; and worse still, the 
quality of medicines manufactured cannot be 
guaranteed. The effects of inadequate pharmaceutical
production capacity including substandard medicines
are not only limited to Uganda but directly impact the 
poor especially in African, Asian, and Latin American 
countries, on a global scale.
Universal Health Coverage, target 3.8 of the United 
Nations post-2015 Sustainable Development Goals
(SDGs) incorporates access to safe, effective, quality,
and affordable essential medicines by 2030 (WHO, 
2015). However, substandard and falsified medical
products represent a severe problem for public health,
especially in Africa, South-East Asia, and Latin America.
United Nations Industrial Development Organization 
(UNIDO) believes that strengthening the pharmaceutical
manufacturing industry in Africa contributes directly to 
improved access to quality-assured, affordable, safe,
and efficacious essential medicines (UNIDO, 2010).
Adherence to Good Manufacturing Practices (GMP) in 
addition to establishment of quality assurance systems
contribute to the consistent manufacture of high-quality
drugs. National Medicine Regulatory Authorities (NMRA)
are mandated to inspect facilities regularly to ensure 
compliance with these GMP practices. The GMP
inspection process may include but not limited to the 
following parameters: pharmaceutical quality
management; qualification and validation; product
market complaints and recalls; self-inspection, quality
and supplier audits; personnel; premises, equipment and
utilities; documentation; production, outsourced
activities and quality control (WHO, 2007).
Pharmaceutical companies located in developing
countries, including Uganda, frequently feature 
operating environments and procedures that fall below
acceptable standards. These are depicted in the non-
conformances noted during GMP regulatory inspections.
According to the WHO multi-country study of 2002 on 
effective drug regulation, Uganda pharmaceutical
manufacturing plants inspected had 60% GMP
violations, which reflected serious problems regarding
GMP compliance and implementation. This has been 
attributed to the lack of robust quality assurance systems
among local pharmaceutical companies to manufacture 
quality products. The concept of quality culture in most
of these companies is almost non-existent. As a result,
locally made pharmaceuticals are generally perceived to 
be of low quality compared to imported ones.
Substandard medicines are manufactured through poor
production practices and controls not following GMP and 
could also be deliberately done for commercial gains
with disregard to the safety of the patient. Johnston and 
Holt, 2013 noted that substandard drugs may have 
variable formulations between different batches of the 
same drug or between generic and branded drugs,
incorrect amounts of API in the drug, drug related 
impurities and degradation products. The extent of
knowledge of health workers and consumers to be able 
to identify substandard drugs is unknown.
Data from different studies on the quality of medicines in 
Uganda and Africa, in general, has been collated to 
provide evidence on substandard drugs, including those 
manufactured locally. According to WHO, about 10% of
the medications in the global medicine market, and more
than 25% in developing countries, are 
substandard/falsified with antibiotics and antimalarials
being the most frequent. A systemic review and meta-
analysis of databases on the prevalence and estimated
economic burden of substandard and falsified medicines
in low and middle-income countries indicated that 19.1%
of the antimalarials and 12.4% of antibiotics were 
falsified, with an estimated economic impact within a
range of $10-$200 billion (Ozawa S., 2018). In a study
on the quality of antimalarials in six African countries,
Bate et al., (2008), reported 35% of the tested medicines
from Uganda were substandard.
High infant mortality rates in Uganda, among other
things, are caused by substandard and falsified drugs,
stock outs of essential drugs, and provision of
pharmaceutical services through unlicensed pharmacies
and drug shops by unqualified practitioners (Gilbert O. et 
al., 2015). In a survey by Renschler (2015), there were
120,000 deaths of children under-five, annually, that may
be associated with the consumption of poor-quality
antimalarials in sub-Saharan Africa alone. The risk of
harm from receiving substandard or falsified medicines
is high in vulnerable populations and patients with 
comorbidities. In 1990, 109 Nigerian children died as a 
result of administering them adulterated Paracetamol
syrup by their parents, and the incidents happened due
to the manufacturer’s negligence by replacing genuine 
solvent with the counterfeit solvent that contained a 
deadly level of Diethylene Glycol, which is a known 
human toxicant and is commonly used in industries for
non-edible items (Aminu and Gwarzo, 2017). The effects
of substandard and falsified medicines imply that even
the rich may not survive the health consequences given
the complex supply chain systems among African
countries.




    
 











    
 
   
  
   





   
     
 
     
      
      
  
 












    
  
     
 
    
   
  
   
 
 





     
 
  
   
   




    
  
   
   
      
   
 
   
   
  
    




   
 
   
 
  
     
   
    
     
  





   
  
 
       
     
 
not safe, efficacious and are of poor quality. These 
medicines lead to poor treatment outcomes,
antimicrobial resistance and sometimes adverse drug
reactions. This indirectly increases the treatment costs
and hence becomes a burden to the general population 
(Geyer et al., 2019). The burden of substandard
medicines is therefore linked to the wastage of resources
which could have benefitted public health and increase
economic productivity.
Failure to comply with GMP and subsequent production
of substandard drugs may also have a direct effect on 
the reputation of the company as there would be
increased customer complaints, recalls and production 
waste. The company may also face regulatory penalties
and the summation of all this leads to decreased
profitability and loss of market share (Geyer et al., 2018).
Failures are inevitable in any company; however,
systems have to be established that provide for detailed
investigation to identify the root cause for the reported 
non-conformance or failure in order to take appropriate 
corrective and preventive actions (CAPA) to avoid 
recurrence and improve the system. Biswas K., 2007 
highlighted that about 30-50% of FDA-483 forms raised 
were related to CAPA deficiencies and the situation is
not any better in developing countries.
National Medicines Regulatory Authorities (NMRA’s)
have a direct bearing on GMP implementation by local
pharmaceutical industries to manufacture safe and 
quality medicines. In Uganda, the National Drug 
Authority inspects local pharmaceutical industries for
GMP compliance. Therefore, improvements have to be 
made in the regulatory systems of the country which 
would directly translate into a strong regulated 
pharmaceutical industry boosting production of quality
medicines locally.
This study identified the non-conformances during 
regulatory inspections and gaps in the production of local
pharmaceuticals with the overall objective to promote the 
growth of the domestic pharmaceutical industry in 
Uganda through improved compliance to GMP
requirements
2. METHODS
This study adopted a quantitative study design with 
categorization and quantification of the non-
conformances obtained from a review of the available 50 
GMP inspection reports for 21 local pharmaceutical
companies in Uganda since 2016. The non-
conformances were categorized as per the GMP
inspection parameters defined by the WHO GMP
guidelines, and guidance to GMP by Pharmaceutical
Inspection Cooperation Scheme (PIC/S). All data were
entered into an Excel database and analyzed.
Binary logistic generalized estimating equations (GEE)
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model was applied to estimate the association between 
odds of a company failing to comply with GMP
requirements and non-conformances under each GMP
inspection parameter. Based on the GMP requirements,
nine variables (GMP inspection parameters) were
selected for testing their association with failure to 
comply. Based on the likelihood-ratio (LR), a stepwise 
forward selection was used to build a multivariable model
from the nine variables, retaining those variables with p-
values < 0.2. The primary outcome of this model was the 
conclusion on GMP, as “failed=1” and “passed=0”. Six
variables remained significant after adjusting for other
related factors. These included:
1) Pharmaceutical quality management;
2) Personnel; 
3) Premises, equipment, and utilities;
4) Quality control; 
5) Self-inspection; quality and supplier audits and 
6) Complaints and recalls.
Dummy estimation to linear regression was used to 
analyze the relationship that existed between the 
selected variables (GMP inspection parameters) and the 
production capacity of the local pharmaceutical industry.
The dummies for production capacity, which were the 
independent variables, were created holding a “large 
scale” as the base variable. The model was run
independently across all the selected variables. A total
of 9 variables (GMP inspection parameters) were tested 
for the relationship with the production capacity of the 
industry
3. RESULTS AND DISCUSSION
3.1. Production Capacity
The production capacity for the local pharmaceutical
companies in Uganda was classified based on the 
number of employees, the criteria used by Söderbom &
Teal (2004) in the classification of African firms. The 
results indicated that 52% of the surveyed local
manufacturers were small scale, 29% medium scale,
and 19% large scale as shown in Table 1.
  
  
         
    
   
     
Table 1: Production Capacity of Local Pharmaceutical Industries in
Uganda, 2019
Type of Industry No. of Employees No. of Industries
Small Scale Below 30 11(52%)
Medium Scale 31-99 6(29%)
Large Scale Above 100 4(19%)
The number of local pharmaceutical manufacturers
increased from 11 in 2009 (UNIDO, 2010) to 21 in 2019.
There has been a significant increase in the industries at
a small-scale level from 9% in 2009 to 52% in 2019 and 
a decrease in medium-scale and large-scale industries
from 55% to 29% and 36% to 19% respectively, in




   
 
       
  
  
   
  
      
  
   
 
 
   
 
    
   
     
 











   
   
 









   






   
   
  
   
  
 
      




    
    
    
    
 
 
       
 
 
     
 
   




   
 
       
     
1: Criticality of GMP Non-conformances during Regulatory 
Inspections 
■ Minor Non-conformances 
■ Major Non-conformances 
■ Critical Non-conformances 
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Data from the 2nd East African Community Region 
Pharmaceutical Manufacturing Plan (EACRPMP),
according to the 2014 estimates, indicated that Uganda
had a pharma size market of about 450 Million USD at
8.5% annual growth. Therefore, the potential for a
booming and economically viable pharmaceutical
industry is high. However, as per the results, only small-
scale investments have been attracted over the past
nine years in the Uganda pharma industry. Worse still,
two medium-scale pharma companies have since closed 
business in the same time period, which needs to be 
analyzed further to seek possible remedies to this
unbecoming trend.
3.2. Scope of manufacturing
Two facilities manufactured Beta-Lactam products,
specifically Penicillins. According to the NDA GMP
guidelines on medicinal products, INS/GDL/001, highly
sensitizing materials (e.g., Penicillins) are required to be 
manufactured in dedicated and self-contained facilities.
The two facilities had segregated facilities where these 
products were produced. However, reviewed reports had
critical non-conformances related to inadequate 
containment systems of the air handling units on the 
Beta-Lactam sections, which posed a potential threat of
cross-contamination.
Three manufacturing units were established in hospitals
and lacked quality control facilities that were required for
the products manufactured. Besides, one of the medical
devices’ manufacturing facility also had no quality control
laboratory. In all these facilities, there was no clear policy
on the outsourcing of quality control activities, which 
increased the possibility of the release of products not
meeting specifications onto the market. This is in 
contradiction with the quality control requirements as per
GMP guidelines.
Five facilities manufactured medical devices. However,
there are no laws and regulations on the manufacturing
of medical devices in Uganda although a unit to work on 
these gaps has since been established.
There were three manufacturing facilities for veterinary
products, including a specialized facility for veterinary
vaccines. The non-conformances, some critical, of the
facility have demonstrated the struggles in the 
establishment of sterility assurance systems and 
maintenance of the required environmental conditions
during production.
Only one large scale manufacturer was WHO accredited 
under the prequalification program for medicines
(Antimalarials and Anti-Retroviral Drugs), which 
translates into the high level of GMP compliance
compared to other non-accredited pharmaceutical
companies in the country. Prequalification increases the 
market share beyond the country to other regional
markets; and, participation in global procurements, as 
the quality of products manufactured, is guaranteed
(WHO,2014). Pharmaceuticals manufactured in Uganda 
are exported to regional markets under the East African 
Community with support of the Uganda Investment
Authority (UIA). This expanded market provides an 
opportunity to develop the pharmaceutical industry
(UNIDO,2010).
The majority of these companies manufactured oral
liquids (9), liquids for external use (8), powders, creams
and ointments (5), and tablets (4); while large volume 
parenterals were manufactured in only one facility. The 
results are not different from the UNIDO, 2010 report,
where the majority of local manufacturers specialized in 
oral and topical liquid preparations. The number of
facilities that manufactured a given dosage form was
proportional to the complexity of the manufacturing 
process. For example, only one facility was involved in 
the production of parenteral products. Specialized 
medical products like oral morphine and Anti-Retroviral
Drugs (ARVs) were each manufactured in at least one
facility while one of the hospital manufacturing units had 
sterile eye preparations.
3.3. GMP Non-conformances
All GMP inspection reports for local pharmaceutical
industries completed from 2016-2019 had non-




   
  
       
  
   
   
      
    




   
    
  
      
      









    
     
    
 
    
   
 
     
    
   




   
 
   
  
     
 
  




    
  
  
   
 
 
   




        Table 2: Regression results using dummy estimations comparing
      pharmaceutical production capacity and criticality of Non-
 conformances
 Variable  D_large   D_small P-Value   D_medium P-value
 Critical Non-
 conformances  1.0  1.40  0.34  0.84  0.120
 Major Non-
 conformances  1.0  6.77  0.02  8.40  0.040
 Minor Non-
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conformances totaling 1,758, an average of 35 non-
conformances per the report, or approximately 84 non-
conformances per inspected facility. Routine 
inspections
were done once a year unless special investigations
were required. In the follow up investigations by the
regulator, there was scanty evidence of implementation
of Corrective Action and Preventive Actions (CAPA) by
majority of the local manufacturers. This demonstrated
inadequate commitment and exposed laxity to
improving domestic production through regulatory
compliance.
Of the non-conformances, 86% were categorized as
Major, 11% were Minor, and 3 % were Critical, as shown 
in Figure 1. The regression results, as per Table 2,
showed that major non-conformances were significantly
higher in small scale industries, (B=6.77, P=0.02) and
medium scale industries (B=8.40, P=0.04) as compared
to large scale industries. It was also revealed that large 
scale industries had significantly higher minor non-
conformances as compared to small scale (B=-4.12,
P=0.03) and medium scale industries (B=-3.8, P=0.001).
The majority of the non-conformances were under the 
categorization of “Major.” Some of the non-
conformances were incorrectly classified in comparison 
to the GMP guidelines. Numerous “Major” non-
conformances would indicate a failure in quality
assurance systems and these would otherwise be 
critical, leading to the closure of the facilities. However,
this was not the case and implied that the acceptable 
cGMPs were not adequately enforced in a bid to promote 
the local pharmaceutical manufacturers, a critical
balance that may result in negative consequences on
the quality of locally pharmaceutical products.
Weak enforcement of GMPs directly leads to production 
of substandard and or falsified medicines. Therefore, in 
agreement with Johnston & Holt, 2013, the key to ensure
quality of drugs manufactured locally is the
implementation of robust regulatory systems by the
NMRA.
Table 3: GMP Inspection Outcomes/Conclusions
Type of No. of GMP No. of GMP No. of GMP
Industry reports reports for CAPA reports with
approved before approval failure
conclusion
Small Scale 2 13 6
Medium Scale 0 12 1
Large Scale 0 16 0
Total 2(4%) 41(82%) 7(14%)
3.4. GMP Inspection outcomes/conclusions
GMP inspection outcomes/conclusions for the reviewed 
reports in Table 3 indicate that only 4% were GMP
approved after the initial inspection, but the majority
(82%) had to submit CAPA before approval, while 14%
failed meeting GMP requirements. Manufacturers that
fail to meet GMP standards have to cease operations
since this puts the public in danger of exposure to 
substandard drugs. Failure to comply with GMP is not a 
criminal offense as per the Uganda National Drug Policy
and Authority Act (NDP/A Act, Cap 206) compared to the 
USA, where FDA defines the minimum Good 
Manufacturing Practice standards, upheld by law (21
CFR part 211). Therefore, the enforcement of GMPs
among the local pharmaceutical industry in Uganda 
need to be strengthened. Furthermore, licensing of a 
local manufacturing facility was not directly tagged to the 
results of the GMP inspection, which needs to be
reviewed following the associated possible risks.
non-conformances




Premises and equipment and Utilities 
Personnel 
Self Inspection and quality and supplier audits 
Complaints and recalls 


















   
  
     
    
    














        







    
 
  
     
  
  
   
 
      
       
     
     
 
     
  
 
   




   
 
    
  
                     
       
      
      
      
      
      
      
       
 
  
     
                    Table 4: Logistic regression model showing likelihood of failure to comply with GMP due to non-conformances per given GMP parameter
Variable/GMP inspection parameter Average cOR P-Value aOR P-Value
Pharmaceutical quality management 0.72 2.21 0.013 3.26 0.003
Personnel 1.68 3.86 0.016 5.73 0.001
Premises and equipment and utilities 5.42 4.20 0.034 6.81 0.001
Documentation 8.50 1.11 0.399 - -
Production 10.44 1.06 0.213 - -
Quality control 6.12 3.14 0.021 5.32 0.003
Outsources activities 0.40 0.85 0.74 - -
Complaints and recalls 0.82 2.23 0.019 3.82 0.023
Self-inspection and quality and supplier audits 0.98 2.26 0.029 5.97 0.001
cOR= Crude Odds Ratio, aOR= adjusted Odds Ratio
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3.5. GMP Inspection Parameters and
associated Non-conformances
The common areas of non-conformances were
Production (30.1%), Documentation (24.5%), Quality
control (17.6%), and premises, equipment and utilities
(15.5%) as per Figure 2. Results contrast to a similar
study carried out in Brazil by Geyer et al., 2019, where the 
most common areas of deficiency were qualification and 
validation (35.1%), documentation (32.2%), premises
(26.4%), and quality control (23.5%). For the case of this
study in Uganda, non-conformances under qualification 
and validation were incorporated under documentation.
The two studies indicate similarities in problems faced by 
manufacturers regarding documentation and quality
control. Documentation non-conformances have also 
been highlighted in most of the FDA-483 forms and this
appears to be a challenging fact for the pharmaceutical
manufacturers globally (Geyer et al, 2019).
Non-conformances related to quality control activities are 
highly cited in Uganda due to lack of adequate human
resources, equipment, and technology to meet the current
standards, for example, no laboratory among local
pharmaceutical manufacturers is accredited to ISO 17025 
standard. Quality control analysis of medicines is critical
in confirmation of the quality of the medicine as per the
defined pharmacopeial specifications.
Non-conformances under production were the major
violations for Uganda, mainly due to the basic methods
employed in the processes with minimal technological
advancements to meet current developments. Poor raw
and packaging materials quality and storage, poor
equipment designs and maintenance, inadequate 
procedures, incompetent personnel, lack of validated 
cleaning processes, poor premises maintenance, and lack
of process validations among others directly affected the 
production processes. A full commitment is required by
the local manufacturers to address these problems in
order to produce quality products.
The results from the logistic regression model in Table 4
significantly showed that for every non-conformance 
under premises, equipment, and utilities, there was a 7-
fold likelihood of failing to comply with the GMP
requirements (aOR=6.81, P=0.001); and, there was also 
a five times likelihood that a firm was unable to conform to 
GMP, for any non-conformance related to quality control
(aOR=5.32, P=0.003). The majority of the medium and
small scale industries had poor controls for the 
manufacturing environments, which impacted directly on 
the quality of the products. Many even lacked air handling
units to provide recommended manufacturing
environments.
Furthermore, per the results in Table 5, it was found that
the non-conformances relating to premises, equipment,
and utilities were significantly higher in small-scale
(B=2.29, P=0.04) and medium-scale industries (B=2.02,
Table 5: Regression results using dummy estimations comparing pharmaceutical production capacity and non-conformances per given
GMP inspection parameter
Variable/GMP inspection parameter D_large D_small P-Value D_medium P-value
Pharmaceutical quality management 1.0 0.43 0.52 0.49 0.879
Personnel 1.0 1.16 0.38 0.70 0.208
Premises and equipment and utilities 1.0 2.29 0.04 2.02 0.045
Documentation 1.0 0.99 0.26 -0.31 0.729
Production 1.0 2.83 0.84 3.22 0.428
Quality control 1.0 -1.41 0.03 1.89 0.008
Outsources activities 1.0 -0.92 0.02 -1.17 0.005
Complaints and recalls 1.0 0.22 0.20 0.81 0.162
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Quality control Self inspection and
quality and supplier 
P=0.045) compared to large-scale industries. The majority
of medium and small-scale industries had poorly designed 
premises. Conversely, large-scale industries had
significantly more non-conformances relating to quality
control as compared to small scale (B=-1.41, P=0.03) and 
the medium scale industries (B=1.89, P=0.008). The 
quality control laboratories in large-scale facilities were 
not in tandem with the testing requirements for
manufactured products. However, for some medium and 
small-scale industries, quality control activities can be 
considered non-existent. Finally, the non-conformances in 
outsourced activities were significantly more in large-scale
industries than small-scale (B=-0.92, P=0.02) and
medium-scale industries (B=-1.17, P=0.005).
Generally, the number of non-conformances per GMP
inspection parameters observed during regulatory
inspections has increased over the past three years since 
2016, per the trending results shown in Figure 3. 
Evidence of recurring GMP problems among the local
pharmaceutical industries also demonstrated weak
corrective and preventive actions (CAPA) implementation 
systems.
Quality risk assessment of critical production and quality
control of pharmaceuticals provides guidance on the
appropriate CAPA. However, the principles of root cause 
analysis and risk assessment with linkage to the effect on 
the final consumer (patient) are often not exploited by the 
Figure 3: GMP non-conformance trends from 2016 to 2018 
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system would include identification of the non-
conformances with trend analysis followed by evaluation
of the potential impact using risk assessment tools on the 
quality of the product. Investigations including root cause 
analysis with adequate supportive data would be
conducted to guide development of the CAPA plan which 
has to be verified for its effectiveness (Menon N. et al,
2016).
3.6. Local pharmaceutical production – Gaps 
and opportunities
Caudron et al., (2008) noted that, much efforts have
been geared towards the fight against counterfeit drugs
but the problem of substandard drugs has been given
less attention. Post market surveillance for such drugs is
inadequate as few samples of locally manufactured 
pharmaceuticals are analyzed in a given period. Locally
based pharmaceutical industries are also challenged 
with poor recall systems in cases of failure following 
laboratory analysis and this exposes patients to 
substandard drugs.
2ndThe East African Community Regional
Pharmaceutical Manufacturing Plan (EACRPMP) 2017-
2027 highlights that local pharmaceutical production in
sub-Saharan Africa contributes only 30% of the 
medicinal products demand. The inability to meet this



















local manufacturers as emphasis is often on correction of unfair competition of locally manufactured products with
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violations to GMPs by local pharmaceutical
manufacturers, inadequate human and financial
resources; lack of modern technologies and equipment
and weak regulatory systems, and a lack of enabling 
policies (including policy coherence) among various
sectors (both nationally and regionally). These are the 
same findings as per the report on local pharmaceutical
production by Bate R., (2008).
Overcoming these barriers would boost local
pharmaceutical manufacturing and offer several
advantages, including continuous supply of
pharmaceuticals, reduction on overdependence on 
importations, increased technical capacity, availability of
labor and increased revenue. Sufficient local production
of quality medicines would contribute to reduced 
morbidity and mortality rates and overall growth of the
pharmaceutical industry to the benefit of the final
consumer- the patient as quality medicines would be 
available at affordable rates. Dansie et al., 2019 reported 
that Uganda had introduced a 12% import tax on a 
selected drugs that Ugandan pharmaceutical industries
already manufactured under the “Buy Uganda, Build
Uganda” as one of the policies to boost local production 
of pharmaceuticals. The regulator is also required to
continue with the efforts of building capacity of the local
manufacturers to meet GMP requirements and build 
quality into their products during the entire 
manufacturing cycle.
4. CONCLUSION
Domestic pharmaceutical manufacturers’ challenges
with regards to the implementation of cGMPs and quality
assurance systems, are enormous. They would require 
the regulator to design a special risk-based inspection
and supervision model on the follow-up of GMP non-
conformances during regulatory inspections among local
manufacturers.
Commitments to GMP compliance with timelines have to
be made in a phased manner and adhered to between 
the manufacturers and the regulator to boost the 
domestic production of quality pharmaceuticals in 
Uganda. Again, the regulators have to put in place 
appropriate legal framework to enforce GMPs among 
local pharmaceutical manufacturers. This would go a 
long way in building confidence of the general population 
in locally manufactured pharmaceuticals and in the work
of the regulator.
5. RECOMMENDATIONS FOR NEXT
STEPS
The regulator has to collect and analyze data based on
implementation science to determine the extent of
substandard drugs manufactured locally in Uganda. This
would provide national medicine regulatory authorities
with information on the scale of the problem for reference 
to base practical and applicable regulatory decisions to 
local pharmaceutical manufacturers.
National Medicine Regulatory Authority (NMRA) has to 
engage local pharmaceutical manufacturers on the 
development of the short-term, medium-term, and long-
term strategies to address the non-conformances
observed in regulatory inspections with defined timelines
for implementation and follow-up. The strategies may 
include facilitation of GMP upgrades among local
industries or amendment of the NDP/A Act to provide for
explicit legal consequences against GMP violations.
Manufacturers would be required to conduct a risk
assessment on critical production and quality control
processes based on the GMP non-conformances and 
thereafter develop a CAPA plan whose effectiveness
would be monitored by the regulator. Local
pharmaceutical manufacturers should also be supported 
to build quality management systems that would guide 
implementation of CAPA plans in a sustainable way.
Refresher GMP training for the local pharmaceutical
manufacturers need to be conducted more frequently
based on the findings on GMP non-conformances during 
inspections.
NMRA should continue to participate in harmonization
initiatives in medicine regulation including the East
African Community to achieve regulatory convergence 
not only in GMP inspections but also medicine dossier
assessments and registration, quality control analysis,
post market surveillance and pharmacovigilance within 
the region and optimally benefit from sharing the 
available limited resources. WHO has recently
introduced a system of evaluation of NMRA’s using a 
Global Benchmarking Tool (GBT) as a means of
strengthening regulatory systems on medical products
and this would also be beneficial to the NMRA.
A study on the quality of locally manufactured products
should be undertaken to determine the extent of
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